Fig. 4

Anti-cancer effect of rbNPs in peritoneal dissemination model mice. (A) Flow diagram for the evaluation of the anti-cancer effect of rbNPs in peritoneal dissemination model mice. Colon26/fluc cells are transplanted to the peritoneal cavity of mice, and rbNPs are injected with three cycles of 3 daily injections and 1 injection-free day between cycles. At day 12, mice are subjected to in vivo imaging. (B) In vivo imaging of colon26/fluc cells in mice. Mice are anesthetized, and injected with VivoGlo™ Luciferin, and the luminescence derived from colon26/fluc cells in mice is detected. (C) The sum intensity of luciferase activity is calculated based on the images of Fig. 4B. Results are expressed as the mean ± SD of three or six. #p < 0.01. ns, not significant. (D) Body weight changes of mice. The body weight of mice is measured daily. Results are expressed as the mean ± SD of three or six mice. *p < 0.05 vs. NT group; ns, not significant. (E) Fluorescence images of mouse organs harvested 15 min, 1, 3, 6, and 24 h after injection of DiR-rbNPs or DiR. BALB/c mice are intraperitoneally injected with DiR-rbNPs or DiR. At 15 min, and one, three, six, and 24 h after injection, the fluorescence intensity of organs is visualized using an in vivo imaging system